Tango Therapeutics Inc (NASDAQ:TNGX) shares traded down 3.1% on Thursday . The stock traded as low as $8.35 and last traded at $8.41. 1,251 shares traded hands during trading, a decline of 99% from the average session volume of 137,788 shares. The stock had previously closed at $8.68.
TNGX has been the subject of several recent analyst reports. SVB Leerink initiated coverage on Tango Therapeutics in a report on Monday, September 20th. They issued an “outperform” rating for the company. Zacks Investment Research raised Tango Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 23rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $16.50.
The business’s fifty day simple moving average is $10.89.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Citigroup Inc. acquired a new position in Tango Therapeutics in the third quarter valued at approximately $41,000. Penserra Capital Management LLC bought a new stake in shares of Tango Therapeutics during the third quarter valued at approximately $133,000. Victory Capital Management Inc. bought a new stake in Tango Therapeutics during the third quarter worth $143,000. Cubist Systematic Strategies LLC bought a new stake in Tango Therapeutics during the third quarter worth $204,000. Finally, Bank of New York Mellon Corp bought a new position in Tango Therapeutics in the 3rd quarter valued at $326,000. 88.40% of the stock is currently owned by hedge funds and other institutional investors.
About Tango Therapeutics (NASDAQ:TNGX)
Tango Therapeutics Inc is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc, formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.